Journals / Selçuk Tıp Dergisi / 2007 / Cilt: 23 - Sayı: 2

Immunopathology of multiple sclerosis

Multipl sklerozun immünopatolojisi

Pages
99–107
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: MS occurs with different immünopat-hological mechanisms.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Multiple sclerosis (MS) is an immune- mediated disease of the central nervous system.
📊
Key Findings & Data:The inflammation in MS appears to be caused by an overactive pro-inflammatory TH1 profile in T cells.
💡
Conclusion & Impact:Conclusion: MS occurs with different immünopat-hological mechanisms.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Aksonlar · Multipl skleroz · Demiyelinizan hastalıklar

Abstract

Aim: Multiple sclerosis (MS) is an immune- mediated disease of the central nervous system. We will emphasize in this article; very different mechanisms, and complex interactions have important role in immunopathology of multiple sclerosis. Main Findings: The pathogenesis of MS is best viewed as a complex interaction between genetically predetermined susceptibility markers and environmental stimuli. MS is charecterized by inflammation, demyelination, apoptosis in oligodendrocytes, rem-yelination, and axon loss. Immune reaction against different components of the central nervous system (particularly myelin structures) are thought to play an important role in the initiation of the destructive process. The inflammation in MS appears to be caused by an overactive pro-inflammatory TH1 profile in T cells. Demyelination can result as a consequence of direct damage to myelin by inflammatory cells or indirectly because of the enviroment produced by inflammation. Axon loss occurs in MS lesions starting early in the disease. Conclusion: MS occurs with different immünopat-hological mechanisms.

Özet

Amaç: Multipl skleroz (MS) santral sinir sisteminin (SSS) immün aracılı hastalığıdır. Biz bu makalede MS'nin immünopatolojisinde çok farklı mekanizmalar ve kompleks etkileşimlerin önemli role sahip olduğunu vurgulayacağız. Ana Bulgular: MS'nin patogenezi çevresel uyaran ve genetik olarak yatkınlık arasında kompleks etkileşimin en iyi görünümüdür. MS inflamasyon, demiyelinizasyon, oligo-dendrosit apopitozu, remiyelinizasyon ve akson kaybıyla karekterizedir. SSS'nin farklı komponentlerine (miyelin striktürleri) karşı immün reaksiyon destrüktif proçesin başlamasında önemli role sahiptir. MS'de inflamasyon proinflamatuvar TH1 profilinde T hücrelerinin sayesindedir. Demiyelinzasyon, inflamasyonla oluşan çevrenin indirekt etkisi veya inflamatuvar hücrelerce miyelinin direkt hasarı neticesinde gelişebilir. Akson kaybı, hastalıkta MS lezyonlarının erken başlangıcında görülür. Sonuç: MS farklı immünopatolojik mekanizmalarla gelişir.

🔖

Cite This Article

AKPINAR, Z., AKÇA, A. H. (2007). Immunopathology of multiple sclerosis. Selçuk Tıp Dergisi, Cilt: 23 - Sayı: 2, 99–107. https://ajindex.com/articles/319659

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (18)

  1. Ge Y, Grossman Rl, Udupa JK. Magnetization transfer ratio histogram analysis of normal appearing gray matter and normal appearing white matter in multiple sclerosis. J Comput Asist Tomogr 2002
  2. 26(1): 62-8 2.Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005
  3. 747 3.Alexandre P, Jack A. Pathogenesis of multiple sclerosis. Curr Opin Neurol 2005
  4. 30 4.Edward J.Fox. Immunolopathology of multiple sclerosis. Neurology 2004
  5. 63(6): 3-7 5.Lassmann H, Bruck W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis implications for diagnosis and therapy. Trends Mol Med 2001
  6. 21 6.Lassmann H. Mechanisms of demyelination and tissue destruction in multiple sclerosis. Clin Neurol Neurosurg2002
  7. 71 7.Lucchinetti C, Bruck W, Parisi J. Implications for the pathogenesis of demyelination. Ann Neurol 2000
  8. 17 8.Zhou D, Hemmer B. Specificity and degeneracy: T cell recognition in CNS autoimmunity. Mol Immunol 2004
  9. 33 9.Hemmer B, Vergelli M, Tranquill L, Conlon P, Ling N, McFarland HF, Martin R. Human T-cell response to myelin basic protein peptide (83-99): extensive hetero¬ geneity in antigen recognition, function, and phenotype. Neurology 1997
  10. 49(4): 11 16- 26 10.Kim HJ, Antel JP, Duquette P. Persistence of immune responses to altered and native myelin antigens in patients with multiple sclerosis treated with altered peptide ligand. Clin Immunol 2002
  11. 14 11.İdiman E. Santral sinir sisteminin miyelin hastalıkları: Oğul E
  12. ed. Klinik Nöroloji. Birinci baskı. İstanbul: Nobel & Güneş Tıp Kitabevi
  13. 70 12.Comabella M, Balashov K, Issazadeh S, Smith D,Weiner HL, Khoury SJ. Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. J Clin Invest 1998
  14. 102(4): 671- 8 13.Chitnis T, Khoury SJ. Neuroimmunology. In: Bradley WG, Daroff RB, Fenichel GM, Jankovic J
  15. eds. Neurology in clinical practice. 4nd ed. Philadelphia: But- terworth Heinemann
  16. 5 14.Nakajima H, Fukuda K, Doi Y, Sugino M, Kimura F,Hanafusa T, Ikemoto T, Shimizu A. Expression of TH1 /TH2-related chemokine receptors on peripheral T cells and correlation with clinical disease activity in patients with multiple sclerosis. Eur Neurol 2004
  17. 52(3):162-8 15.Torres BA, Kominsky S, Perrin GQ, Hobeika AC, Johnson HM. Superantigens: the good, the bad, and the ugly. Exp Biol Med (Maywood) 2001
  18. 226(3): 164- 76 16.Minagar A, Alexan